T
Teresa M. Hesley
Researcher at Merck & Co.
Publications - 16
Citations - 4438
Teresa M. Hesley is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vaccination & Cervical intraepithelial neoplasia. The author has an hindex of 12, co-authored 16 publications receiving 4256 citations. Previous affiliations of Teresa M. Hesley include Ludwig Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Journal ArticleDOI
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years
Darron R. Brown,Susanne K. Kjaer,Kristjan Sigurdsson,Ole-Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo L. Pérez,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven-Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Elmar A. Joura,Robert J. Kurman,Slawomir Majewski,N. Munoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine Bryan,Lisa Lupinacci,Katherine E. D. Giacoletti,Heather L. Sings,Margaret James,Teresa M. Hesley,Eliav Barr +35 more
TL;DR: These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and -18 and are needed to fully ascertain the population-based impact and public health significance of these findings.
Journal ArticleDOI
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
Nubia Muñoz,Susanne K. Kjaer,Kristjan Sigurdsson,Ole Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Suzanne M. Garland,Sepp Leodolter,Sven Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Warner K. Huh,Elmar A. Joura,Robert J. Kurman,Slawomir Majewski,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Lisa Lupinacci,Katherine E.D. Giacoletti,Heather L. Sings,Margaret James,Teresa M. Hesley,Eliav Barr,Richard M. Haupt +39 more
TL;DR: High-coverage HPV vaccination programs among adolescents and young women may result in a rapid reduction of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures and in the longer term, substantial reductions in the rates of cervical, vulvar, and vaginal cancers may follow.
Journal ArticleDOI
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
Joakim Dillner,Joakim Dillner,Susanne K. Kjaer,Cosette M. Wheeler,Kristjan Sigurdsson,Ole Erik Iversen,Mauricio Hernández-Ávila,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Matti Lehtinen,Marc Steben,F. Xavier Bosch,Elmar A. Joura,Slawomir Majewski,Nubia Muñoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Roger Maansson,Shuang Lu,Scott Vuocolo,Teresa M. Hesley,Eliav Barr,Richard M. Haupt +36 more
TL;DR: Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types and a substantial reduction in the burden of these diseases through 42 months of follow-up.
Journal ArticleDOI
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Susanne K. Kjaer,Kristjan Sigurdsson,Ole-Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven-Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Matti Lehtinen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Elmar A. Joura,Elmar A. Joura,Slawomir Majewski,Nubia Muñoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Roger Maansson,Shuang Lu,Scott Vuocolo,Teresa M. Hesley,Alfred J. Saah,Eliav Barr,Richard M. Haupt +37 more
TL;DR: The efficacy of quadrivalent HPV vaccine against high-grade cervical and external anogenital neoplasia remains high through 42 months post vaccination, and effectiveness in the intention-to-treat population tended to be lower in older women, women with more partners, and women with abnormal Pap test results.